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doi:10.1016/j.jtcvs.2008.01.040168 The Journal of Thoracic and CardObjectives: The right ventricle fails quickly after increases in its afterload (ie, pulmo-
nary hypertension) compared with the left ventricle (ie, systemic hypertension),
resulting in significant morbidity and mortality. We hypothesized that the poor perfor-
mance of the hypertrophied right ventricle is caused, at least in part, by a suboptimal
mitochondrial/metabolic remodeling.
Methods/Results: We studied mitochondrial membrane potential, a surrogate for
mitochondrial function, in human (n5 11) and rat hearts with physiologic (neonatal)
and pathologic (pulmonary hypertension) right ventricular hypertrophy in vivo and in
vitro. Mitochondrial membrane potential is higher in the normal left ventricle com-
pared with the right ventricle but is highest in the hypertrophied right ventricle,
both in myocardium and in isolated cardiomyocytes (P , .01). Mitochondrial
membrane potential correlated positively with the degree of right ventricular hypertro-
phy in vivo and was recapitulated in phenylephrine-treated neonatal cardiomyocytes,
an in vitro model of hypertrophy. The phenylephrine-induced mitochondrial hyperpo-
larization was reversed by VIVIT, an inhibitor of the nuclear factor of activated T lym-
phocytes, a transcription factor regulating the expression of several mitochondrial
enzymes during cardiac development and hypertrophy. The clinically used drug di-
chloroacetate, known to increase the mitochondria-based glucose oxidation, reversed
both the phenylephrine-induced mitochondrial hyperpolarization and nuclear factor
of activated T lymphocytes (NFAT) activation. In Langendorff perfusions, dichloroa-
cetate increased rat right ventricular inotropy in hypertrophied right ventricles (P ,
.01) but not in normal right ventricles, suggesting that mitochondrial hyperpolarization
in right ventricular hypertrophy might be associated with its suboptimal performance.
Conclusions: The dynamic changes in mitochondrial membrane potential during right
ventricular hypertrophy are chamber-specific, associated with activation of NFAT,
and can be pharmacologically reversed leading to improved contractility. This mito-
chondrial remodeling might provide a framework for development of novel right ven-
tricle–specific therapies.
A
lthough mechanisms of left ventricular (LV) heart failure are widely docu-
mented, right ventricular (RV) failure remains understudied, despite its
high clinical importance. RV dysfunction is a major cause of morbidity
and mortality in many conditions, including pulmonary arterial hypertension
(PAH), congenital heart disease, and lung transplant surgery.1,2 In response toiovascular Surgery c July 2008




LV 5 left ventricle/ventricular
LVH 5 left ventricular hypertrophy
NFAT 5 nuclear factor of activated T lymphocytes
PAAT 5 pulmonary artery acceleration time
PAH 5 pulmonary arterial hypertension
RV 5 right ventricle/ventricular
RVH 5 right ventricular hypertrophy
SMC 5 smooth muscle cells
TMRM 5 tetramethyl–rhodamine methyl ester
increased afterload (as seen in PAH), the thin RV of the nor-
mal adult heart hypertrophies but eventually quickly dilates
and fails. There are, however, situations in congenital heart
disease wherein the RV remains hypertrophied and compen-
sated for years despite the development of PAH. These cases
are typically seen when there is no involution of the physio-
logic neonatal RV hypertrophy (RVH) and the fetal morphol-
ogy persists through adulthood. In contrast, the normal adult
LV can develop hypertrophy and remain in a compensated
state in response to an increase in its afterload (systemic hy-
pertension) for decades. The relatively early failure of the RV
in pulmonary hypertension explains largely the much worse
survival of patients with PAH compared with patients with
systemic hypertension; at the same time, this raises the excit-
ing possibility that something in the neonatal hypertrophied
RV (normal remodeling) offers superior function and protec-
tion compared with the acquired RVH in adults with PAH
(abnormal remodeling).3 The cause of this early failure re-
mains unknown and understudied and explains the lack of
RV-specific therapies.1,2
We have recently described that phosphodiesterase 5 in-
hibitors, such as sildenafil, may be RV-specific inotropes.4
This theory is based on the fact that phosphodiesterase type
5 is selectively expressed in the myocardium of the hypertro-
phied RV but not in the LV of the same animal.4 In the search
for better RV-specific therapies, as opposed to the LV, iden-
tification of differences between the two ventricles is critical.
There are several studies examining the metabolism of the
LV,5,6 but there is an impressive lack of studies on the metab-
olism of the RV. There is some evidence for differences be-
tween the metabolism of the RV and LV, at least in hypoxic
animals.7 Potential differences in the metabolism or molecu-
lar biology between the two ventricles are not surprising
given the recent discovery that the two ventricles have a dif-
ferent origin at early embryogenesis of the heart; whereas the
RV develops from the anterior heart field, the LV develops
from the early heart tube.8 It is therefore not appropriate to
extrapolate findings or conclusions from the LV to the RV.
Also, the adaptation of the RV to increased afterload mayThe Journal of Thorbe regulated by mechanisms different from those in the
LV.9 The need to specifically study RV function and failure
was recently recognized by the National Institutes of Health
as a priority.1
In the neonatal heart, the RV is physiologically hypertro-
phied, in response to the high pulmonary vascular resistance
in utero. However, after birth, the thickness of the RV even-
tually becomes only a third of that of the LV, as the pulmonary
vascular resistance gradually decreases.10 The physiologic
hypertrophy in the neonatal RVmight be regulated by a ‘‘fetal
gene program,’’11 which might be reactivated (at whole or in
part) in adult disease states. Fetal and adult cardiac hypertro-
phy are also characterized by a predominantly glycolytic phe-
notype,5,6,12 which in the LV,13,14 vascular biology,15 or
cancer16 is associated with a resistance to apoptosis. This
has not been studied directly in the RV. The fact that metab-
olism and apoptosis are both directly regulated by mitochon-
dria17 suggests that a potential mitochondrial and metabolic
remodeling might be central to the regulation of RVH.
We hypothesized that there is a chamber-specific and
dynamic mitochondrial remodeling during RVH, which
might be associated with its suboptimal performance; rever-
sal of this mitochondrial remodeling might be beneficial, im-
proving RV function. We studied mitochondrial membrane
potential, a surrogate for overall mitochondrial function
and metabolism,15-19 in human and rat hearts. We used con-
focal microscopy and tetramethyl–rhodamine methyl ester
(TMRM), a positively charged dye that localizes at the
most negative organelles in the cell, the mitochondria.17 Mi-
tochondrial hyperpolarization or depolarization is detected
and quantified by an increase or decrease in TMRM fluores-
cence, respectively. We show that human and rat RVH is
characterized by a dynamic increase in mitochondrial mem-
brane potential (more hyperpolarized than that observed in
the normal RV and LV) and that inhibition of this by the
clinically used metabolic modulator dichloroacetate (DCA,
an inhibitor of the mitochondrial pyruvate dehydrogenase
kinase20) increases inotropy in the hypertrophied RV, but
not in the normal RV. Our work has significant translational
potential as DCA is being used in humans with mitochondrial
diseases21 and has recently been shown to reverse mitochon-
drial hyperpolarization, increase glucose oxidation, and re-
verse disease phenotype in both cancer16 and PAH.15
Methods
Complete details are available online in the E-Supplement Methods
section.
Permission from the University of Alberta committees on human
ethics and animal policy and welfare was attained for all experi-
ments on human and rat tissues, respectively.
Human Heart Tissue Samples
Human samples were acquired from patients undergoing surgery for
congenital heart disease or transplantation at the University ofacic and Cardiovascular Surgery c Volume 136, Number 1 169
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ETAlberta Hospital. Excised ventricular tissue samples (free wall) were
immediately placed on ice and stained with TMRM and Hoechst (a
nuclear stain) for 40 minutes and visualized under confocal micros-
copy.15,16,19 The presence of hypertrophy was documented by the
use of echocardiography for every patient (Table 1) and confirmed
macroscopically by the surgeon.
Animal Model of RVH
We studied RVH using a model of experimental PAH by injecting
monocrotaline, an alkaloid from Crotalaria spectabilis, a widely
established rat PAH model, as previously described15,19 (E-Supple-
ment Methods).
Isolation of adult rat cardiomyocytes. Adult Sprague–Dawley
rats (300–350 g) were used and cardiomyocytes were isolated
from the ventricles as previously described4 (E-Supplement
Methods).
Isolation and culture of neonatal rat cardiomyocytes. Neonatal
Sprague–Dawley rat pups, 2 days old, were used to isolate RV
and LV cardiomyocytes, which were then separated from fibroblasts
and placed in culture, as previously described22 (E-Supplement
Methods). Immunocytochemistry for myosin heavy chain con-
firmed that the studied cultured cells were cardiomyocytes (Supple-
ment Figure E1).
Staining and confocal microscopy of cells and tissues. TMRM
was made up to a concentration of 20 nmol/L in plating media along
with 0.5 mmol/L of Hoechst nuclear stain. Each 35 mm 3 10 mm
plate of cells received 2 mL of the staining solution for a period
of 30 minutes at 37C. For ventricular rat tissue, the exposure was
40 minutes. The staining media was then removed, and each plate
was rinsed and left at 37C in another 2 mL of plating media. Stain-
ing of plates was staggered to give each plate from each ventricle the
same amount of exposure to TMRM and the same amount of time
before imaging.
Immunohistochemistry and confocal microscopy were performed
on a Zeiss LSM 510 multiphoton confocal microscope (Carl Zeiss,
Inc, Jena, Germany) using antigen retrieval and Image enhancer IT
(Invitrogen Corporation, Carlsbad, Calif) for nuclear factor of acti-
vated T lymphocytes (NFATc3) and 4,6-diamino-2-phenylindole
(DAPI, a nuclear stain) as previously described4,15,16,19,23 (also see
E-Supplement Methods).170 The Journal of Thoracic and Cardiovascular Surgery c JulyIsolated rat RV Langendorff perfusion. Adult rats with normal
and hypertrophied heart (owing to monocrotline-induced PAH)
were used. The heart were removed and perfused in a modified Lan-
gendorff preparation designed to study RV contractility, as we re-
cently described4 (also see E-Supplement Methods).
Statistics
Comparison between LV and RV cardiomyocytes (from either neo-
natal or adult models) was done with a t test. Analysis of ventricular
tissue (from either adult rat or human) and neonatal cultured neona-
tal cardiomyocytes was completed via 1-way analysis of variance
with post hoc Bonferroni correction.
Results
Dynamic and Chamber-specific Increase in
Mitochondrial Membrane Potential in Human
and Rat RVH
We first examined fresh human myocardial samples that were
excised during surgical procedures within 30 minutes of
excision. We obtained tissues from 11 patients with normal
or hypertrophied RVs based on preoperative echocardiogra-
phy (RV free wall thickness, Table 1). Wewere able to secure
tissues from only two normal RVs and LVs. All specimens
were loaded with TMRM and handled and imaged under
identical conditions. There was increased TMRM fluores-
cence in the normal LV samples compared with the RV
from the same patient (Figure 1, A). There was also increased
TMRM fluorescence in RVH samples compared with the
normal RV (Figure 1, B and C). Because we were able to se-
cure only two normal hearts, direct comparisons among
groups cannot be performed. However, results observed in
the rat ventricular tissues were similar to the human RV
and LV samples, where the normal adult rat LV had a higher
mitochondrial membrane potential than the RV (Figure 2, A;
P, .01). To determine whether this was due to differences in
cardiomyocytes, rather than other cells (ie, fibroblasts), we
isolated rat adult RV and LV cardiomyocytes. Indeed, theTABLE 1. Tissues obtained From 11 patients with normal or hypertrophied RVs
Patient Age, sex Diagnosis Tissue
RV
thickness (cm)
1 19 y, F Left atrial sarcoma; heart transplant Normal LV, normal RV 0.3
2 46, y M RV failure after heart transplant; repeat heart transplant Normal LV —
3 54, y M Intractable angina, no PAH, moderate LVH; heart transplant Normal RV 0.4
4 4 m, F Tetralogy of Fallot; surgical specimen RVH 1.0
5 3 y, M RV outflow tract obstruction; surgical specimen RVH 1.1
6 5 m, M Tetralogy of Fallot; surgical specimen RVH 0.9
7 58 y, F Rheumatic valve disease; heart transplant RVH 1.6
8 11 d, M Hypoplastic left heart; surgical specimen RVH 0.7
9 2 y, F Coarctation of aorta and ventricular septal defect; surgical specimen RVH 1.0
10 6 m, M Pulmonary stenosis and ventricular septal defect; surgical specimen RVH 0.8
11 4 m, M Tetralogy of Fallot; surgical specimen RVH 0.9
RV, right ventricle; LV, left ventricle/ventricular; PAH, pulmonary arterial hypertension; LVH, left ventricular hypertrophy; RVH, right ventricular hypertrophy.2008
Nagendran et al Evolving TechnologyFigure 1. Differences in mitochondrial
membrane potential between human RV
and LV myocardium. A and B, Confocal mi-
croscopy images of acutely TMRM and
Hoechst loaded normal RV and LV myocar-
dium from patient 1 (A) and normal RV and
RVH from Patients 3 and 6, respectively
(B). C, Mean TMRM fluorescence from all
patients expressed in fluorescence units
per area (n 5 2 RV, n 5 2 LV, n 5 8 RVH).differences in mitochondrial membrane potential from whole
myocardial tissue persisted at the level of individual cardio-
myocytes (Figure 2, B). The mean TMRM fluorescence
data showed a similar increase in myocardial and cardiomyo-
cyte mitochondrial membrane potential in the LV versus the
RV, respectively (Figure 2, C). Although these results are in-
teresting descriptive findings between the two ventricles, the
possibility to exploit these differences in targeted therapeutic
strategies required further assessment of the changes that
occur in disease states.The Journal of ThoTo examine the effects of hypertrophy on mitochondrial
membrane potential, we used the model of monocrotaline-in-
duced PAH and subsequent RVH in the rat. After injection
with monocrotaline, the rat hearts were explanted on day
14 (moderate PAH and RVH) and day 28 (severe PAH and
RVH). RV myocardium was loaded with TMRM and
compared with vehicle-injected control animals (Figure 3).
The worsening RVH was measured by echocardiography
(free-wall thickness) and later confirmed macroscopically at
autopsy (RV/LV 1 septum, data not shown). The increasedETFigure 2. Similar mitochondrial mem-
brane potential differences in adult rat
RV and LV myocardium, also exist in
isolated adult rat RV and LV cardiomyo-
cytes. A, Confocal microscopy images
of adult rat RV and LV myocardium
loaded with TMRM and Hoechst. B, Iso-
lated adult rat RV and LV cardiomyo-
cytes loaded with TMRM and Hoechst.
Merge panels also show differential in-
terference contrast (DIC) channel for
cell surface details. C, Mean TMRM
fluorescence from all rat myocardial
samples (n 5 17 RV, n 5 17 LV; *P <
.01 vs RV myocardium). Mean TMRM
fluorescence for individual cardiomyo-
cytes (n 5 58 RV, n 5 83 LV; *P < .01
vs RV cardiomyocytes). TMRM, Tetra-
methyl–rhodamine methyl ester; DAPI,
4,6-diamino-2-phenylindole.racic and Cardiovascular Surgery c Volume 136, Number 1 171
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ETFigure 3. Mitochondrial membrane potential pro-
gressively increases with the development of
pathologic RVH. Upper third, Pulmonary artery ac-
celeration time (PAAT; hatched bars) progres-
sively decreased from control to 14 days to 28
days after monocrotaline (MCT) injection, while
this was mirrored by a subsequent increase in
RV free wall thickness (solid bars); *P < .01 ver-
sus control; yP < .01 versus RV 14 days after
MCT injection.Middle third,Mean TMRM fluores-
cence from all rat RV myocardial samples with
progression of RVH after MCT injection (n 5 17
control RV, n 5 5 RV 14 days after MCT injection,
n5 11 RV 28 days after MCT injection; *P< .01 vs
control; yP < .01 vs RV 14 days after MCT injec-
tion). Bottom third, Representative confocal
images of RV myocardium loaded with TMRM
and Hoechst.pulmonary artery pressure was shown by measurement of the
pulmonary artery acceleration time (PAAT), which we15,19
have previously shown to correlate negatively with mean pul-
monary artery pressure in simultaneous right heart catheteri-
zation in rats. As hypertrophy progressed, there was
a progressive increase in mitochondrial membrane potential
in a ‘‘dose-dependent’’ manner (Figure 3).
Once again, to determine whether the cardiomyocytes
develop mitochondrial hyperpolarization in hypertrophy and
exclude possible effects of circulating factors in vivo, we
used in vitro models. Neonatal cardiomyocytes (isolated
from the neonatal RV, which is physiologically hypertro-
phied) can be cultured for 48 to 72 hours without significant
change in phenotype, whereas isolated adult cardiomyocytes
cannot be reliably sustained in culture.22 We looked to mimic
pressure overload hypertrophy by exposing cultured neonatal
cardiomyocytes to phenylephrine. In this classic model of hy-
pertrophy, in vitro cardiomyocytes have increased levels of
intracellular calcium and develop hypertrophy within 48
hours.22 Phenylephrine caused the predicted increase in cell
size and a significant increase in mitochondrial membrane
potential compared with vehicle-treated cardiomyocytes (Fig-
ure 4, A). The response to phenylephrine resulted in hyperpo-
larization of the mitochondria similar to that seen in
physiologic RVH (723 6 41 versus 587 6 10 FU/mm2, re-
spectively; P , .01). Although it cannot definitely be ex-
cluded, it is unlikely that phenylephrine led to mitochondria
biogenesis and an increased absolute number of mitochondria172 The Journal of Thoracic and Cardiovascular Surgery c July(which by itself would contribute to the increased TMRM
signal), as the cells were only treated for 48 hours.
We then sought to determine a potential molecular mech-
anism for this mitochondrial remodeling and whether its
normalization would lead to improved RV function.
Molecular and Metabolic Targeting of the Remodeled
Mitochondria in Hypertrophy: The Role of NFAT
The increase in mitochondrial membrane potential in hyper-
trophy is likely multifactorial in etiology. First, there is an in-
crease in intracellular and intramitochondrial calcium. This
leads to activation of many mitochondrial enzymes that in
turn cause an increase in Krebs cycle production of reducing
equivalents, reactive oxygen species, and adenosine triphos-
phate, all of which alter mitochondrial function and
mitochondrial membrane potential. Second, the increase in
cytoplasmic calcium results in activation of the critical tran-
scription factor NFAT,24 which is activated and regulates
anatomic and metabolic remodeling during heart develop-
ment25 and LV hypertrophy (LVH).26 NFAT regulates the
expression of many mitochondrial and metabolic genes (in-
cluding adenylosuccinate synthetase 1,27 pyruvate decarbox-
ylase, heart–fatty acid binding protein, and the electron
transport chain enzymes succinate dehydrogenase and cyto-
chrome c oxidase25). NFAT is critical for heart development,
as knockout of NFAT is fatal by embryonic day 10.5.25 This
transcription factor is highly conserved among species with
the same isoforms found in humans and mice.24 Thus, we2008
Nagendran et al Evolving TechnologyFigure 4. DCA and NFAT inhibition re-
verse the mitochondrial hyperpolariza-
tion seen in RV cardiomyocytes from
physiologic (neonatal RV) and patho-
logic (phenylephrine-induced) hyper-
trophy in vitro. A, Representative
confocal images of neonatal rat cardio-
myocytes treated with vehicle, phenyl-
ephrine (PE), phenylephrine plus
dichloroacetate (PE1DCA), or phenyl-
ephrine plus VIVIT (PE1VIVIT) and
cultured for 48 hours before loading
with TMRM and Hoechst. Mean TMRM
fluorescence for individual cardiomyo-
cytes (n > 140 cardiomyocytes per
treatment; *P < .01 vs control; yP < .01
vs phenylephrine). B, Immunocytochem-
istry performed in fixed neonatal cardi-
omyocytes after phenylephrine or
phenylephrine1VIVIT treatment show
the prevention of nuclear factor of acti-
vated T lymphocytes (NFAT, red) translo-
cation into the nucleus (blue) by VIVIT (n
5 6 plates per group [>150 cells/plate];
*P < .01 vs control; yP < .01 vs phenyl-
ephrine). C, Isolated neonatal rat RV and
LV cardiomyocytes treated with vehicle,
DCA, or VIVIT and cultured for 48 hours
before loading with TMRM and
Hoechst. Mean TMRM fluorescence
for individual cardiomyocytes (n 5 473
LV, n 5 449 RV; *P < .01 vs LV cardio-
myocytes; yP < .01 vs control).ETstudied whether the increase in mitochondrial membrane po-
tential was NFAT dependent by culturing neonatal cardio-
myocytes with phenylephrine and VIVIT (a selective
NFAT inhibitor28). VIVIT abolished the increase in mito-
chondrial membrane potential caused by phenylephrine to
a level similar to that of untreated control neonatal cardio-
myocytes (Figure 4, A). To confirm that VIVIT inhibited
NFAT, we performed immunocytochemistry on fixed neona-
tal cardiomyocytes for NFATc3 (the isoform that has been
studied the most in the heart) and DAPI (nuclear stain).
NFAT activation is associated with a translocation of
NFAT into the nucleus, whereas inhibition of NFAT with
VIVIT restricts NFAT to the cytoplasm.23,24 As expected,
phenylephrine caused translocation of NFAT into the nu-
cleus, whereas treatment with VIVIT inhibited this transloca-
tion and kept NFAT in the cytoplasm (Figure 4, B).
DCA inhibits the mitochondrial enzyme pyruvate
dehydrogenase kinase, which in turn causes increased activ-
ity of pyruvate dehydrogenase, and thus DCA promotes the
influx of pyruvate into the mitochondria, increasing glucose
oxidation. Recently, DCA has been shown to reverseThe Journal of ThorNFAT activation, mimicking the effects of VIVIT in cancer,
increasing glucose oxidation, decreasing mitochondrial
membrane potential in human cancer cell lines, and regress-
ing tumor growth in vitro and in vivo.16 DCA mimicked
VIVIT and caused a decrease in mitochondrial membrane
potential and inhibited the nuclear translocation of NFAT
in the cultured neonatal cardiomyocytes, despite continued
exposure to phenylephrine (Figure 4, A and B). Although
we did not measure metabolism directly, DCA is known to
increase the coupling of glycolysis to glucose oxidation in
the postischemic heart, and although it does not have signif-
icant effects in the normal LV, it improves ischemia–reperfu-
sion recovery in mild LVH.29
To determine whether DCA and VIVIT will depolarize
mitochondria from physiologically hypertrophied hearts (as
in the phenylephrine-induced hypertrophy) and whether
this is ventricle-specific, we harvested neonatal rat hearts
and isolated cardiomyocytes from separated RV (which is
hypertrophied) versus LV (which is not hypertrophied) free
walls. Similar to the adult RVH myocardium from monocro-
taline-induced PAH, the isolated neonatal hypertrophiedacic and Cardiovascular Surgery c Volume 136, Number 1 173
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ETcardiomyocytes from the RV free wall had more hyperpolar-
ized mitochondria than those isolated from the LV free wall
(Figure 4, C). Both DCA and VIVIT reversed this mitochon-
drial hyperpolarization and brought the mitochondrial mem-
brane potential to the levels of the nonhypertrophied LV
cardiomyocyte. Interestingly, DCA and VIVIT had no effect
on the LV cardiomyocyte mitochondria (Figure 4, C).
These data show that in both physiologic and pathologic
RVH, cardiomyocyte mitochondria are hyperpolarized, at
least in part, due to NFAT activation, and that it can be re-
versed by DCA. Does this translate into improved RV func-
tion?
DCA Improves RV Inotropy in RVH
Since several patients with PAH or RVH owing to congenital
heart disease only have affected RVs (their LVs are normal),
the mitochondria-targeting DCA may selectively augment
RV function in the setting of RVH.We used the ex vivo mod-
ified Langendorff perfused heart4 to measure RV contractility
(Figure 5, A). This modified model allows for real-time mea-
surement of ex vivo developed pressures in the perfused RV,
while its preload is constant (the balloon in the RV has a fixed
volume) and is beating against no afterload (pulmonary
artery transected). Interestingly, during perfusion of hearts174 The Journal of Thoracic and Cardiovascular Surgery c July28 days after monocrotaline injection (severe RVH) com-
pared with control animals, there was a significant and
dose-dependent increase in developed pressure in the hyper-
trophied but not the normal RVs, whereas both had a similar
increase in contractility by isoproterenol (Figure 5, B and C).
Compatible with the expected DCA-induced increased
glycolysis-to-glucose oxidation coupling, there was also an
accompanied decrease in coronary effluent lactate only in
the hearts with RVH (Figure 5, D).
Discussion
We describe dynamic and chamber-specific changes in mito-
chondrial function during the development of human and rat
RVH, at the level of both the myocardium and the isolated
cardiomyocyte (Figures 1 and 2). RVH is characterized in
human and rat hearts by increased mitochondrial membrane
potential compared with the normal RV, and this hyperpolar-
ization appears to progress in parallel with the development
of hypertrophy (Figure 3). We used monocrotaline-induced
RV hypertrophy over pulmonary artery banding to better
mimic acquired PAH in humans, where the RV is exposed
to a gradual (not acute) rise in afterload. Even in the setting
of physiologic RVH that occurs in the neonatal heart, RV car-
diomyocytes have more hyperpolarized mitochondria thanFigure 5. Targeted metabolic modula-
tion by dichloroacetate (DCA) acutely
improves RV inotropy in the ex vivo
modified Langendorff perfused heart.
A, Schematic of the isolated perfused
RV (Langendorff preparation) to
measure developed pressure. B, Repre-
sentative real-time traces of the devel-
oped pressures from the normal RV
(upper) and 28 days after monocrotaline
injection RVH (lower) before and after
the addition of DCA into the perfusate
(shaded area). Note the significant in-
crease in developed pressure only in
the RVH hearts with acute DCA treat-
ment. C, Mean data showing that DCA
increased developed pressure (delta
pressure from baseline developed pres-
sure) in a dose-dependent manner in the
RVH (n 5 5) but not the normal RV (n 5
6), whereas both normal and hypertro-
phied RV responded similarly to isopro-
terenol (*P < .01 vs normal RV). D,
Coronary sinus effluent was collected
on ice from the modified Langendorff
perfusions 5 minutes after a steady
baseline was established and 10 min-
utes after initiating perfusion with
DCA and was analyzed for lactate con-
centration (n 5 6 RV, n 5 5 RVH; *P <
.01 vs normal RV; yP < .01 vs baseline).2008
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can be induced in vitro by phenylephrine, which also leads
to significant increases in mitochondrial membrane potential
within 48 hours (Figure 4, A). Interestingly, this hyperpolar-
ization is reversed by inhibition of a crucial transcription fac-
tor, NFAT, which has been shown to play a significant role in
heart development18 and LVH26 but has not been previously
studied in the RV hypertrophy (Figure 4, A and B). Further-
more, directly targeting mitochondria with DCA reversed the
mitochondrial hyperpolarization in hypertrophy (Figure 4)
and led to improved RV function (Figure 5). DCA did not af-
fect the mitochondria and did not increase the contractile
pressure of the normal RV. It is possible that the mitochon-
drial effects that we describe in RVH, both in vivo and in vi-
tro, reflect a suboptimal mitochondrial remodeling, which
may be responsible for suboptimal RV energy production
and the relatively weak response of the RV to increased after-
load. To the best of our knowledge, this is the first time in
which the degree of hypertrophy is correlated to mitochon-
drial membrane potential and inotropic effects of a drug are
related to the level of mitochondrial membrane potential, at
least in the RV.
Although the RV and LV are currently approached and
treated the same from a clinical perspective, the diversity of
mitochondria between the RV and LV is not surprising given
their different embryologic origins8 and the increasing evi-
dence for significant diversity of mitochondria among differ-
ent organs, such as the liver and kidney.30,31 The diversity of
mitochondria extends beyond that of different organs to find
diversity even within individual myocytes.32,33 We34 have
previously shown that differences in mitochondrial function
between the pulmonary and systemic arterial smooth muscle
cells (SMC), where systemic SMC mitochondria are more
hyperpolarized than pulmonary artery SMC mitochondria
and account, at least in part, for the different response of
the two vasculatures to hypoxia (the pulmonary arteries con-
strict whereas the renal arteries dilate). We subsequently
demonstrated that, in PAH, the mitochondrial membrane
potential in the pulmonary artery SMC is hyperpolarized
compared with the SMC mitochondria from normal pulmo-
nary artery SMC. We also demonstrated that treatment with
DCA both normalized mitochondrial membrane potential
and reversed PAH.15,35 It is also intriguing that the prolifer-
ative pulmonary artery SMC from PAH patients also have ac-
tivated (ie, nuclear) NFAT (like the RVH cardiomyocytes),
whereas the normal pulmonary artery SMC smooth do not
(like the normal RV cardiomyocytes).23
The molecular basis for mitochondrial remodeling in
hypertrophy is unknown, although mitochondrial diversity
among other organs is associated with varying degrees of
electron transport chain complex expression, which needs
to be explored between the RV and LV, as well as possible
changes during hypertrophy from the normal ventricles.
We provide preliminary evidence that NFAT might play anThe Journal of Thorimportant role in this mitochondrial remodeling in RVH, sim-
ilar to its recently described role in PAH23 and cancer.16 Our
work cannot exclude the possibility that the increase in mito-
chondrial membrane potential is not due to an increase in mi-
tochondrial number. However, the fact that a short-term
exposure to DCA and VIVIT normalizes the mitochondrial
membrane potential and the fact that DCA acutely improves
RVH function suggests that the increased mitochondrial
membrane potential has a functional basis.
The profile of DCA’s effects in cancer and PAH (where it
selectively increases apoptosis by depolarizing mitochon-
dria) might raise concerns, inasmuch as it might increase
RV apoptosis after long-term use. However, it is remarkable
that long-term use of DCA has been shown to reverse PAH
and RVH and to improve functional capacity and mortality
in several animal PAH models.15,16,36 It is possible that the
DCA-induced mitochondrial depolarization in cardiomyo-
cytes in the hypertrophied RV is enough to lead to improved
contractile function but not enough to induce apoptosis by
itself.
Furthermore, another medication that causes regression of
PAH by inducing apoptosis in pulmonary artery SMC is
sildenafil, which we4 recently showed also increases contrac-
tility in RVH,much like DCA. However, long-term use of sil-
denafil (.2 years) in patients with PAH has not resulted in
any cardiovascular related deaths and has led to improvement
of RV function.37 Nonetheless, this theoretical concernwould
need to be studied properly in the setting of a clinical trial.
The improved contractility of the hypertrophied RV with
DCA is a novel finding. On the basis of the differences of the
mitochondrial function between the two ventricles, we pre-
dicted that the effects of DCA would be restricted to the
hypertrophied RV (and spare the normal RV and the LV). In-
deed, DCA has failed to improve contractility from baseline
in the LV, although there was a better recovery after ische-
mia.29 The lack of improvement in LV contractility with
DCA has also been shown in human studies where patients
with coronary artery disease or congestive heart failure did
not show improved LV contractility or cardiac output with
short-term administration of intravenous DCA.38,39
Our findings that DCA improved RV contractility acutely
might also be relevant to the many clinical conditions in
which RV-specific inotropy is needed, including patients
with postcardiotomy shock who have preoperative RV dys-
function, or in the surgery of pediatric patients with congen-
ital heart disease and RVH.
Limitations
The study ofmitochondrial membrane potential as a surrogate
for mitochondrial metabolism is validated and accepted in the
literature35; however, there are assumptions made using an in
vitro model to represent in vivo findings. Most important, the
in vitro environment of isolated cardiomyocytes does not
mimic in vivo conditions, and although this is a confoundingacic and Cardiovascular Surgery c Volume 136, Number 1 175
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ETfactor, it is common to all isolated cells and we base our
deductions from the delta membrane potential between the
RV, LV, and treatment arms. Another limitation of the study
is the small number of human samples obtained. However,
we believe that these unselected human data are worthy of
presentation because they are in agreement with our data
from several in vivo and in vitro animal models, generally
supporting the relevance of our hypothesis.
Conclusions
Selective agents targeting the diseased RV are highly
desirable, given the poor performance of the RV in states
of pressure overload (congenital heart disease, PAH, and
post-transplant surgery). We provide evidence that therapeu-
tically targeting mitochondria may allow for potential ventri-
cle-specific treatments. This concept may help build the
framework for a new class of drugs designed to affect only
the diseased ventricle (ie, hyperpolarized mitochondria in
RVH) while having little or no impact on the other more nor-
mal ventricle in the same patient. DCA is one such candidate
therapy, which has minimal effects on normal cells through-
out the body and does not significantly change the hemody-
namics of normal animals15; this was also supported by our
finding in the ex vivo perfused hearts, in which treatment
with DCA did not have significant effects on the developed
pressures generated by the normal RV (Figure 5). The docu-
mented effects of DCA in PAH, and now on RVH, raise the
possibility of studying this drug in humans with PAH. The
ability for a combined ‘‘double-hit’’ mechanism, wherein
pulmonary vascular remodeling and PAH are reversed and
at the same time RV function is directly enhanced, will be
very desirable clinically. We recently described a similar
mechanism in which sildenafil dilates the pulmonary circula-
tion in PAH and at the same time directly increases RVH in-
otropy.4 The fact that DCA has been used in humans with
mitochondrial diseases for more than 30 years21 supports
the need for such phase II studies.
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Discussion
Dr Gordon Cohen (Seattle, Wash). Thank you for the opportunity
to discuss this important presentation by Dr Nagendran and his col-
leagues at the University of Alberta. This paper was originally to be
discussed by my department chief, Dr Edward Verrier. Unfortu-
nately, Dr Verrier had to depart from the meeting early, so I will
be discussing this paper in his place. Normally I would thank you
for submitting the paper to me well in advance and allowing me
plenty of opportunity to review it and think about it. Having just re-
ceived the paper last night from Dr Verrier puts me in the unusual
position of thanking you on his behalf for allowing him a lot of
time to think about it, but my response to him is, ‘‘Thanks a lot,
Ed, for the advance notice’’ [laughter].
This interesting set of experiments was designed to determine
whether the mitochondrial metabolism of the RV, the LV, and the
pathologically hypertrophied RV are distinct and unique. If so, the
authors believed that they could represent specific targets for en-
hancing RV performance. This work is consistent with other inves-
tigations from this laboratory looking to identify mechanisms that
could be pharmacologically exploited to improve performance in
the struggling or failing RV. I have a few observations and question
for Dr Nagendran.The Journal of ThorFirst, why did you not study LVH as a more clinically relevant or
prevalent problem? If nothing else, why did you not use LVH as
a positive control? If your hypothesis is correct, then you might ex-
pect that an even greater change in mitochondrial membrane poten-
tial would be seen for LVH versus RVH.
Dr Nagendran. Thank you for your comments. The reason for
specifically studying the RV is that most of the therapeutics that
are used on the RV were only established in the LV, and models
of LVH and changes in metabolism that occur in LVH have been
documented. The changes that we show that are unique to other
studies of LVH are the dramatic change in mitochondrial membrane
potential and also coupling it to the changes in glucose oxidation
when treated with DCA, which has already been checked in an
LVH model. What we hope to show by these experiments is that
there are inherently different methods of remodeling in the RV
that may be less adaptive than the LV. To use LVH as a positive
control is a very valid statement. The models for LVH require either
invasive surgery, which would be aortic banding, or use of a sponta-
neously hypertensive rat that developed LVH, both of which intro-
duced significant other variables to our model. That is why we
studied the RV specifically.
Dr Cohen. Thank you for that explanation. Second, it appears
to me that you are studying three different groups of cells, and I
am not sure they all represent the same thing. First, you are look-
ing at human RV muscle in which hypertrophy was documented
by echocardiography. Presumably, this was an increase in RV
wall thickness. In this group of patients, the increase in wall thick-
ness presumably is something that developed slowly over time.
One of the patients was undergoing a transplant, so presumably
that was a long-term process. In the second group you studied
rats. You had PAH induced with monocrotaline and then appar-
ently humanely killed the rats at 2 or 4 weeks after again confirm-
ing an increase in RV wall thickness. Finally, you studied isolated
neonatal rat myocytes that were exposed to phenylephrine for 2
days. Have you done any additional studies to ensure that you
are not studying, for example, cellular edema at 48 hours in neo-
natal myocytes, increase in cell size at 2 weeks, and cellular hyper-
plasia plus or minus increase in cell size in the chronic state? If
not, are you not concerned that you may be studying three differ-
ent cellular states under the heading of RVH?
Dr Nagendran.Your point is well taken. The individual models
of RVH are distinct. That is why in the monocrotaline-induced
model, which is a pathologic model, we wanted to show correlation
to a physiologic model, which is the neonatal model. In regard to
whether these cells are different, when you treat with phenylephrine
and induce hypertrophy, that does not mimic an in vivo–type exper-
iment where you would have true pressure overload though the met-
abolic profile of all three types of hypertrophy were similar. That is
the commonality between them that allows us to umbrella them
under the category of RVH.
Dr Cohen. You looked at NFAT, which increases interleukin 2
activity during organ rejection. It does not appear, though, that you
looked at any other transcription factors to see whether this was an
NFAT-specific response. Was the response specific to NFAT or was
the NFAT response part of some other more complex process that
you observed?
Dr Nagendran. The reason for targeting NFAT specifically is
that NFAT is critically linked to pathologic hypertrophy and cardiacacic and Cardiovascular Surgery c Volume 136, Number 1 177
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other studies in cancer and in PAH, we showed a direct link of
NFAT being inhibited by DCA. Once we saw the ex vivo perfusions
and the return of function with DCA treatment, we honed in on sim-
ilar mechanisms that were shown true in other organ systems. That is
why we used NFAT, and indeed phenylephrine’s primary method
of causing hypertrophy in vitro is by an increase in intracellular
calcium, which is the activating step for NFAT by binding to
calcineurin.
Dr Cohen. Finally, how does DCA work in this setting? Is the
DCA causing the mitochondria and the hypertrophied RV to func-
tion better, or is it recruiting more mitochondria? Did you do any
studies to quantify the number of mitochondria present in the hyper-
trophied RV versus the normal RV? Is the change that you see in mi-
tochondrial membrane permeability just a reflection of increased
number of mitochondria that are present? What is the actual poten-
tial clinical utility of DCA? Numerous reports have described the
compound as being neurotoxic.178 The Journal of Thoracic and Cardiovascular Surgery c JulDrNagendran.With regard to the number of mitochondria, we
are also doing a concurrent study in which we examine the indi-
vidual complexes along the electron transport chain. We remove
the mitochondria from these cells and perform in vitro studies.
There we find that the protein ratio of mitochondrial proteins to
cardiomyocytes is similar in both the control and hypertrophy
hearts. DCA caused hyperpolarized mitochondria to revert to
a more normal depolarized phenotype after 2 days of treatment.
However, in these data alone, we also have evidence that this re-
version is a functional status rather than a change in actual number
of mitochondria. The biogenesis of mitochondria is even more
complex based on the fact that mitochondria undergo fission
when increased energy demands are sensed, as well as undergoing
fusion during times of stress to form rigid networks. Thus the ab-
solute number of mitochondria might not change, while the func-
tional state does.
Dr Cohen. Congratulations on an interesting study and thanks
for the opportunity to discuss the paper.y 2008
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ETE-Supplement Methods
All experiments on human tissues and rats were obtained
with permission from the University of Alberta committees
on human ethics and animal policy and welfare, respectively.
Human Heart Tissue Samples
Human samples were acquired from patients undergoing
surgery for congenital heart disease or transplantation at the
University of Alberta Hospital. Excised ventricular tissue
samples (free wall) were immediately placed on ice and
stained with TMRM and Hoechst (a nuclear stain) for 40
minutes and visualized under confocal microscopy.E1-E3
The presence of hypertrophy was documented by the use of
echocardiography for every patient (Table 1) and confirmed
macroscopically by the surgeon.
Animal Model of RVH
We studied RVH using a model of experimental PAH by in-
jecting monocrotaline, an alkaloid from Crotalaria spectabi-
lis, a well-established model of rat PAH.E2,E3 Monocrotaline
is selectively toxic to the pulmonary arterial endothelium and
causes significant RVH in 3 to 4 weeks after intraperitoneal
injection. WeE2,E3 have repeatedly confirmed this using
both invasive (right heart catheterization) and noninvasive
(echocardiographic) methods. Here, we also confirmed the
presence of PAH and RVH by echocardiography using
PAAT (a parameter that correlates with mean pulmonary
artery pressure and, used clinically, the shorter the PAAT
the higher the pulmonary artery pressure) and RV free wall
thickness in a short-axis parasternal view.E2,E3 We further
quantified RVH macroscopically at autopsy using the dry
weight ratio of the RV/LV 1 septum.E2,E3 Monocrotaline
is activated in the liver and then absorbed in the pulmonary
vascular bed without significant effects on systemic vascula-
ture or cardiomyocytes. This concern has been examined by
others, showing that all alterations to cardiomyocytes were
specific to the RV owing to the developed PAH and not found
in the LV of the same animals.E4 Also, as monocrotaline
requires activation by the liver, it is not possible to study
the effects of monocrotaline in vitro.
Isolation of Adult Rat Cardiomyocytes
Hearts were taken from male adult Sprague–Dawley rats
(300–350 g) and the aortas were cannulated and hung onto
a perfusion system. Krebs buffer (NaCl, 118 mmol/L; KCl,
4.7 mmol/L; KH2PO4, 1.2 mmol/L; MgSO47H2O, 1.2
mmol/L; CaCl22H2O, 2.5 mmol/L; NaHCO3, 25 mmol/L;
glucose, 5 mmol/L) at pH 7.4 (corrected to temperature 5
37.5C) was antegradely perfused through the coronary
arteries for 5 minutes. Perfusate solution was then switched
to a 2% w/v collagenase (Worthington Biochemical, Lake-
wood, NJ) supplemented Krebs buffer for 20 minutes. The
hearts were then removed from the system, and the two ven-
tricular free walls were surgically separated for myocyteThe Journal of Thoracisolation. After another 5-minute digestion with 2% w/v col-
lagenase, the samples were tritrated with a glass pipette
filtered through a nylon mesh and the filtrate was centrifuged
to yield cardiomyocytes.
Isolation and Culture of Neonatal Rat
CardiomyocytesE5
Hearts from 2-day-old rats were excised and atria were re-
moved. Free walls of LV and RV were isolated and kept sep-
arately in phosphate-buffered saline. Ventricular tissue was
minced in ice cold phosphate-buffered saline solution and
then digested in an enzymatic cocktail containing 2% w/v
collagenase, 0.5% w/v deoxyribonuclease (Worthington
Biochemical), and 2% w/v trypsin (Worthington Biochemi-
cal) for 20 minutes at 37C. After digestion, administering
Dulbecco modified Eagle medium (DMEM)/F12 media
(Sigma, Oakville, Ontario, Canada) supplemented with
20% fetal bovine serum (Sigma) stopped enzymatic reaction.
The mixture was then centrifuged at 800 rpm for 1 minute
at 4C to remove fibroblasts, red blood cells, and debris in
the supernatant. The pellet was redigested 2 to 3 times for
another 20 minutes and centrifuged at 800 rpm to separate
cardiomyocytes into the supernatant. The collected superna-
tant was finally pooled and centrifuged twice for 7 minutes at
1700 rpm to yield a pellet of cardiomyocytes. Owing to the
quick attachment of fibroblasts to the plates compared with
the rate of attachment of cardiomyocytes, we separate any ex-
isting fibroblasts in the mixture by removing the cardiomyo-
cyte-rich supernatant from the fibroblasts attached to the
plates (differential plating) for 2 hours at 37C. The efficacy
and specificity of this procedure have been previously vali-
dated by our group.E5 The isolated neonatal rat cardiomyo-
cytes were plated and maintained for 2.5 days in DMEM/
F12 media supplemented with 5% fetal bovine serum, 10%
horse serum (Invitrogen Canada Inc, Burlington, Ontario,
Canada), and 50 mg/L gentamicin (Invitrogen). Media also
contained 10 nmol/L cytosine arabinoside (Sigma) to prevent
fibroblast proliferation. Cultured cells were treated for 48
hours with 10 mmol/L phenylephrine to induce cardiomyo-
cyte hypertrophy as previously described.E5 Phenylephrine-
treated cells were also treated with either 5 mmol/L DCA
or 4 mmol/L 11Arg-VIVIT (a competing peptide that selec-
tively inhibits NFAT by blocking its binding to calcineur-
inE6) (EMD Biosciences, Mississauga, Canada); the high
arginine content of the peptide significantly enhances its
permeability into the cell.
Staining of Cells and Tissue
TMRMwas made up to a concentration of 20 nmol/L in plat-
ing media along with 0.5 mmol/L of Hoechst nuclear stain.
Each 35 mm 3 10 mm plate of cells received 2 mL of the
staining solution for a period of 30 minutes at 37C. For ven-
tricular rat tissue, the exposure was 40 minutes with tissues
sliced between 140 and 160 mm in thickness. The stainingic and Cardiovascular Surgery c Volume 136, Number 1 178.e1
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media and then left at 37C in another 2 mL of plating media.
Staining of plates was staggered so as to give each plate from
each ventricle the same amount of exposure to TMRM and
the same amount of time before imaging. Imaging on confo-
cal microscopy was performed at excitation of 543 nm, emis-
sion of 565 to 615 nm, and pixel scale of 0.9 mm3 0.9 mm.
Background fluorescence was accounted for by usual tech-
niques of setting the background to levels of control tissue
that were not stained with TMRM. Photobleaching was not
a significant factor inasmuch as regions where a short time
course was obtained for quantifying TMRM fluorescence
were only imaged once, avoiding the repeated imaging that
causes photobleaching. Also, areas used for quantification
of fluorescence were not imaged in high magnification,
which also predisposes to photobleaching.
Immunohistochemistry and confocal microscopy were
performed using antigen retrieval and Image enhancer IT (In-
vitrogen) for NFATc3 and DAPI (a nuclear stain), as previ-
ously described.E1-E3,E7,E8
Isolated Rat RV Langendorff PerfusionE8
Adult Sprague–Dawley rats (300–350 g) were anesthetized
with intraperitoneal injection of 60 mg/kg pentobarbital. A
midline sternotomy was performed, and within less than 30
seconds the heart was isolated and the aorta was cannulated
and perfused with Krebs buffer at 12 to 13 mL/min. The
hearts had a mean intrinsic rate of approximately 180 to
190 beats/min (hearts with a native rate ,160 beats/min
were not used). A latex balloon (Harvard Apparatus, Saint-
Laurent, Quebec, Canada) was filled with water by titration
to a constant volume of 30 mL and was placed in the RV
via the right atrium through the tricuspid valve. The latex bal-
loon was attached to a pressure transducer (Cobe, Richmond
Hill, Ontario, Canada), and pressure traces were sampled at
a rate of 1000 Hz by PowerLab data acquisition systems.
Pressure readings were analyzed with Chart 5.4 software
(ADInstruments Inc, Colorado Springs, Colo).
Imaging and Analysis of Data
All imaging was performed with a Zeiss LSM 510 confocal
microscope. So that physiologic activity and viability of the
tissue would be maintained, imaging was done on a heated
platform at 37C. Densitometry was analyzed with Zeiss Im-
age Browser software. Fluorescence intensity of TMRMwas
assessed by measuring circular regions of interest (0.126178.e2 The Journal of Thoracic and Cardiovascular Surgery cmm2 in area). A region of interest was drawn into each field
of view where the circle encompassed myocardial tissue only
and not coronary vessels. For cardiomyocytes, the TMRM
intensity was measured in each cell excluding the area con-
taining the nucleus (as marked by Hoechst stain in blue)
and divided by the cytoplasmic area. Phenylephrine-induced
hypertrophy leads to increases in area cytoplasmic area by
35% to 50% after 48 hours of treatment in neonatal cardio-
myocytes (n 5 400–450), whereas in freshly isolated adult
myocytes from animals with RVH, there was an increase of
12% (n 5 56) in cell size compared with control adult RV
cardiomyocytes.
Comparison between LV and RV cardiomyocytes (from
either neonatal or adult model) was done using a t test. Statis-
tical analysis of ventricular tissue (from either adult rat or
human) and neonatal cultured neonatal cardiomyocytes was
completed via 1-way analysis of variance with post hoc Bon-
ferroni correction. All mean data are presented in bar graphs
with standard errors representing variance.
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confocal microscopy image of isolated neonatal rat cardiomyo-
cytes stained for myosin heavy chain (green) and DAPI (blue) to
confirm the cell isolation methods were specific for attaining car-
diomyocytes over fibroblasts and/or vascular cells, with more
than 97% of cells staining positive for myosin heavy chain.ET
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